Across the biotech and life science space, the same pattern keeps appearing. The science moves first. The capital follows. Approval, plant, listing. And then the company finds itself playing two games at once: still being a science company, starting to become a commercial one.

Most of the energy stays with the first. The second is backfilled in fragments.

From the outside that looks coherent. From the inside, the operating reality drifts further from the science by the quarter. The work that closes the drift is rarely glamorous. It sits in the layer underneath. How decisions move from the board to a Friday afternoon. How an offtake on a slide becomes a litre on a truck. How a buyer who has never heard of the company learns about you.

Most companies treat each of those as a separate workstream. The CFO writes the financing narrative, the COO holds the supply, the CCO drives the launch, marketing redesigns the website. The board reads four reports. The market reads one company.

The work is to make it one again. To rebuild the layer between the science and the market as a single piece, deliberately, where it had been built in fragments. To close the distance between what the science has earned and what the rest of the company can actually do.

This is the layer we work on. With leadership, alongside the people already running the company. The first conversation is usually less about a programme and more about understanding the shape of that layer, and where the highest-leverage move actually sits.